Head-to-head evidence
177Lu-RAD204 vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
177Lu-RAD204
Developed by Radiopharm Theranostics, Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06305962 (registry estimate)
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Marketed by Roche
NCT03735121 · Phase 3 · completed
This was a randomized, open-label, active-controlled phase 3 study comparing subcutaneous atezolizumab with the established IV formulation in previously treated NSCLC. The primary endpoints were pharmacokinetic measures (serum trough concentration and AUC) rather than clinical outcomes, and the non-inferiority comparisons were met for both. Because the study was open-label and the primary endpoints were surrogate PK measures, the evidence is limited despite the randomized design and adequate sample size.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 177Lu-RAD204's landscape · Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)'s landscape